Scientific News Boston Scientific Corporation Bsx Gains 44 Ytd As Farapulse Launch Drives 17 Q2 Growth
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Corporation Bsx Gains 44 Ytd As Farapulse Launch Drives 17 Q2 Growth is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
A strong growth profile gives Boston Scientific Corp. (BSX) a favorable outlook
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be ... Read More
Is Boston Scientific Corp. (BSX) positioned for solid, durable growth?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ... Read More
Boston Scientific announces results for third quarter 2025
To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ... Read More
Analyst Visit Confirms Growth Potential for Boston Scientific Corporation (BSX), Buy Rating Retained
Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen ... Read More
Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion. The medical technology giant reported ... Read More
UBS Reiterates Buy Rating on Boston Scientific (BSX)
Boston Scientific Corporation (NYSE: BSX) is one of the 14 Best Large Cap Stocks to Invest In Now. On December 17, UBS reiterated its Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept ... Read More
Boston Scientific Gains Momentum As Growth Broadens, Goldman Sachs Says
The Boston Scientific Analyst: Analyst David Roman reiterated a Buy rating and price target of $120. The Boston Scientific Thesis: The company's total sales grew 20.3% year-on-year to around $5.1 ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus